PT3227297T - Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus - Google Patents

Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus

Info

Publication number: PT3227297T
Authority: PT; Portugal
Prior art keywords: pyrazines; pyrazolo; substituted; kinase inhibitors; janus kinase
Prior art date: 2014-12-05

Application number

PT158199331T

Other languages

English (en)

Original Assignee

Array Biopharma Inc

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-04

Publication date

2021-04-09

2015-12-04 Application filed by Array Biopharma Inc, Celgene Corp filed Critical Array Biopharma Inc

2021-04-09 Publication of PT3227297T publication Critical patent/PT3227297T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)

PT158199331T 2014-12-05 2015-12-04 Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus PT3227297T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462088068P	2014-12-05	2014-12-05

Publications (1)

Publication Number	Publication Date
PT3227297T true PT3227297T (pt)	2021-04-09

Family

ID=55069089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT158199331T PT3227297T (pt)	2014-12-05	2015-12-04	Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus

Country Status (29)

Country	Link
US (3)	US10189845B2 (pt)
EP (2)	EP3227297B1 (pt)
JP (2)	JP6641373B2 (pt)
KR (1)	KR20170090476A (pt)
CN (1)	CN107278203B (pt)
AU (1)	AU2015357585B2 (pt)
BR (1)	BR112017011798A2 (pt)
CA (1)	CA2969709A1 (pt)
CL (1)	CL2017001422A1 (pt)
CO (1)	CO2017006674A2 (pt)
CR (1)	CR20170309A (pt)
DK (1)	DK3227297T3 (pt)
ES (1)	ES2865483T3 (pt)
HR (1)	HRP20210501T1 (pt)
HU (1)	HUE054371T2 (pt)
IL (1)	IL252656A0 (pt)
MX (1)	MX2017007284A (pt)
MY (1)	MY191016A (pt)
PH (1)	PH12017501032A1 (pt)
PL (1)	PL3227297T3 (pt)
PT (1)	PT3227297T (pt)
RS (1)	RS61693B1 (pt)
RU (2)	RU2742938C2 (pt)
SG (1)	SG11201704542SA (pt)
SI (1)	SI3227297T1 (pt)
TW (1)	TWI725004B (pt)
UA (1)	UA120065C2 (pt)
WO (1)	WO2016090285A1 (pt)
ZA (1)	ZA201704494B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY191016A (en)	2014-12-05	2022-05-28	Array Biopharma Inc	4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
WO2017144995A1 (en) *	2016-02-24	2017-08-31	Pfizer Inc.	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
US11028080B2 (en)	2016-03-11	2021-06-08	Denali Therapeutics Inc.	Substituted pyrimidines as LRKK2 inhibitors
PE20190395A1 (es)	2016-06-16	2019-03-13	Denali Therapeutics Inc	Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
GB201617758D0 (en) *	2016-10-20	2016-12-07	Almac Discovery Limited	Pharmaceutical compounds
JP6888101B2 (ja) *	2017-01-18	2021-06-16	アレイバイオファーマインコーポレイテッド	ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
US20200157081A1 (en) *	2017-05-24	2020-05-21	Denali Therapeutics Inc.	Compounds, compositions and methods
WO2019034973A1 (en)	2017-08-14	2019-02-21	Pfizer Inc.	PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
WO2019143991A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11472802B2 (en)	2018-01-18	2022-10-18	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111971286B (zh)	2018-01-18	2023-04-14	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CA3111984A1 (en)	2018-09-10	2020-03-19	Array Biopharma Inc.	Fused heterocyclic compounds as ret kinase inhibitors
CA3136468A1 (en) *	2019-04-12	2020-10-15	Primegene (Beijing) Co., Ltd.	Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors
KR20230031981A (ko)	2019-05-14	2023-03-07	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113150012B (zh) *	2020-01-22	2023-03-24	浙江海正药业股份有限公司	吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
CN115715194A (zh)	2020-04-04	2023-02-24	辉瑞公司	治疗冠状病毒疾病2019的方法
KR20230092863A (ko)	2020-06-11	2023-06-26	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN118317960A (zh) *	2021-11-12	2024-07-09	海南康哲美丽科技有限公司	吡唑并环化合物及其应用
WO2024235167A1 (zh) *	2023-05-12	2024-11-21	海南康哲美丽科技有限公司	一种吡唑并吡嗪类化合物及其晶型的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA01001893A (es)	1998-08-21	2002-04-24	Parker Hughes Inst	Derivados de quinazolina.
DE102007032349A1 (de)	2007-07-11	2009-01-15	Bayer Healthcare Ag	Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
GEP20156243B (en) *	2009-12-23	2015-02-10	Takeda Pharmaceutical	Fused heteroaromatic pyrrolidinones as syk inhibitors
US9073927B2 (en) *	2010-01-22	2015-07-07	Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii	Inhibitors of PI3 kinase
UY33213A (es) *	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
US20110241987A1 (en) *	2010-04-01	2011-10-06	Smart Technologies Ulc	Interactive input system and information input method therefor
NZ603446A (en) *	2010-04-14	2014-05-30	Array Biopharma Inc	5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
JP2014528475A (ja) *	2011-10-12	2014-10-27	アレイバイオファーマ、インコーポレイテッド	５，７置換イミダゾ［１，２−ｃ］ピリミジン
EA027416B1 (ru) *	2012-03-28	2017-07-31	Мерк Патент Гмбх	Бициклические пиразиноновые производные
MY191016A (en)	2014-12-05	2022-05-28	Array Biopharma Inc	4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

2015
- 2015-12-04 MY MYPI2017702034A patent/MY191016A/en unknown
- 2015-12-04 EP EP15819933.1A patent/EP3227297B1/en active Active
- 2015-12-04 WO PCT/US2015/064062 patent/WO2016090285A1/en active Application Filing
- 2015-12-04 TW TW104140878A patent/TWI725004B/zh not_active IP Right Cessation
- 2015-12-04 HU HUE15819933A patent/HUE054371T2/hu unknown
- 2015-12-04 US US15/532,937 patent/US10189845B2/en active Active
- 2015-12-04 RU RU2017123387A patent/RU2742938C2/ru active
- 2015-12-04 SG SG11201704542SA patent/SG11201704542SA/en unknown
- 2015-12-04 SI SI201531544T patent/SI3227297T1/sl unknown
- 2015-12-04 CA CA2969709A patent/CA2969709A1/en not_active Abandoned
- 2015-12-04 RS RS20210415A patent/RS61693B1/sr unknown
- 2015-12-04 CR CR20170309A patent/CR20170309A/es unknown
- 2015-12-04 PT PT158199331T patent/PT3227297T/pt unknown
- 2015-12-04 BR BR112017011798A patent/BR112017011798A2/pt not_active IP Right Cessation
- 2015-12-04 RU RU2021102805A patent/RU2021102805A/ru unknown
- 2015-12-04 UA UAA201707008A patent/UA120065C2/uk unknown
- 2015-12-04 CN CN201580066136.5A patent/CN107278203B/zh not_active Expired - Fee Related
- 2015-12-04 AU AU2015357585A patent/AU2015357585B2/en not_active Ceased
- 2015-12-04 ES ES15819933T patent/ES2865483T3/es active Active
- 2015-12-04 KR KR1020177018122A patent/KR20170090476A/ko unknown
- 2015-12-04 PL PL15819933T patent/PL3227297T3/pl unknown
- 2015-12-04 DK DK15819933.1T patent/DK3227297T3/da active
- 2015-12-04 MX MX2017007284A patent/MX2017007284A/es unknown
- 2015-12-04 JP JP2017529681A patent/JP6641373B2/ja not_active Expired - Fee Related
- 2015-12-04 EP EP21152373.3A patent/EP3878451A1/en not_active Withdrawn
2017
- 2017-06-02 PH PH12017501032A patent/PH12017501032A1/en unknown
- 2017-06-04 IL IL252656A patent/IL252656A0/en active IP Right Grant
- 2017-06-05 CL CL2017001422A patent/CL2017001422A1/es unknown
- 2017-06-30 CO CONC2017/0006674A patent/CO2017006674A2/es unknown
- 2017-07-03 ZA ZA2017/04494A patent/ZA201704494B/en unknown
2018
- 2018-12-06 US US16/212,493 patent/US10730880B2/en active Active
2019
- 2019-12-11 JP JP2019223760A patent/JP2020055859A/ja active Pending
2020
- 2020-06-02 US US16/890,663 patent/US11028093B2/en active Active
2021
- 2021-03-29 HR HRP20210501TT patent/HRP20210501T1/hr unknown

Also Published As

Publication number	Publication date
AU2015357585A1 (en)	2017-07-13
CA2969709A1 (en)	2016-06-09
JP6641373B2 (ja)	2020-02-05
RU2017123387A (ru)	2019-01-11
EP3227297B1 (en)	2021-01-20
AU2015357585B2 (en)	2020-07-02
EP3227297A1 (en)	2017-10-11
JP2018507167A (ja)	2018-03-15
US10189845B2 (en)	2019-01-29
SG11201704542SA (en)	2017-07-28
TWI725004B (zh)	2021-04-21
WO2016090285A1 (en)	2016-06-09
CO2017006674A2 (es)	2017-10-20
KR20170090476A (ko)	2017-08-07
US20200291039A1 (en)	2020-09-17
ES2865483T3 (es)	2021-10-15
EP3878451A1 (en)	2021-09-15
CN107278203B (zh)	2020-05-19
DK3227297T3 (da)	2021-04-06
CN107278203A (zh)	2017-10-20
PL3227297T3 (pl)	2021-10-25
IL252656A0 (en)	2017-07-31
SI3227297T1 (sl)	2021-04-30
HRP20210501T1 (hr)	2021-05-14
CR20170309A (es)	2018-02-02
RS61693B1 (sr)	2021-05-31
BR112017011798A2 (pt)	2017-12-26
ZA201704494B (en)	2022-03-30
RU2742938C2 (ru)	2021-02-11
RU2017123387A3 (pt)	2019-06-03
RU2021102805A (ru)	2021-02-12
US20170362240A1 (en)	2017-12-21
MY191016A (en)	2022-05-28
US20190177328A1 (en)	2019-06-13
PH12017501032A1 (en)	2017-11-27
US11028093B2 (en)	2021-06-08
CL2017001422A1 (es)	2018-01-05
US10730880B2 (en)	2020-08-04
UA120065C2 (uk)	2019-09-25
HUE054371T2 (hu)	2021-09-28
MX2017007284A (es)	2017-08-25
JP2020055859A (ja)	2020-04-09
TW201632523A (zh)	2016-09-16

Publication	Publication Date	Title
ZA201704494B (en)	2022-03-30	4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
IL277576A (en)	2020-11-30	Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
HK1258905A1 (zh)	2019-11-22	作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物
IL265918B (en)	2021-01-31	Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
ZA201901034B (en)	2021-06-30	Macrocycle kinase inhibitors
IL254224A0 (en)	2017-10-31	7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL252053A0 (en)	2017-07-31	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
PL3305788T3 (pl)	2021-03-08	Inhibitor kinazy janusowej
PL3555074T3 (pl)	2022-11-07	Aminopirazole jako selektywne inhibitory kinaz janusowych
IL290419B (en)	2022-10-01	Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL252986A0 (en)	2017-08-31	5,3-diaminopyrazole kinase inhibitors
GB201613945D0 (en)	2016-09-28	Compounds useful as kinase inhibitors